Has Christopher Cooper received payments from drug or device companies?

Yes. Drug and device makers reported $238,596 in general payments to Christopher Cooper across 68 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Christopher Cooper did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Christopher Cooper come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Christopher Cooper

Pulmonary Disease · Los Angeles, CANPI 1588680482

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $222,991 of the $238,596 with a category attached, or 93.5%. 8 manufacturers reported payments, led by Astrazeneca UK Limited at 58.1% of the total. Reporting peaked in 2024 at $102,406 and has fallen 84.3% since, to $16,086 in 2025. Among pulmonary disease clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$238,596in general payments, 2019–2025

Across 68 payments — averaging $3508.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Astrazeneca UK Limited$139K
GSK$56K
Medical Graphics Corporation$29K
Pulmonx Corporation$11K
Amgen$3K
Chiesi USA, Inc.$713
plus $47 from 2 others

$35,590in research payments, 2019–2025

Across 8 payments — averaging $4448.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Genentech, Inc.$20K
Amgen$16K

What the payments were for

Consulting fees$222,99193%
Speaking & faculty fees$5,1502%
Travel & lodging$8,0763%
Food & beverage$1,5281%
Gifts$8510%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Astrazeneca UK Limited	28	$138,709
GSK	24	$56,034
Medical Graphics Corporation	6	$29,450
Pulmonx Corporation	5	$11,078
Amgen	2	$2,567
Chiesi USA, Inc.	1	$713
Boehringer Ingelheim	1	$33
AbbVie	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$238,596 in reported general payments places this provider in the 95th percentile of 1,261 pulmonary disease providers in California.

See all pulmonary disease providers in California →

Other pulmonary disease in Los Angeles

Toby MaherLos Angeles$1.3M
Victor TapsonLos Angeles$514K
Rajan SaggarLos Angeles$480K
Igor BarjaktarevicLos Angeles$337K
Scott OhLos Angeles$252K
John BelperioLos Angeles$224K
Robert StrieterLos Angeles$173K
Roy ArtalLos Angeles$152K
Donald TashkinLos Angeles$141K
Jameel HouraniLos Angeles$116K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →